ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets

Nature Communications

Volumn 4, Issue , 2013, Pages

  Carlos, Ana Rita ^a,d   Escandell, Jose Miguel ^a,d   Kotsantis, Panagiotis ^a,e   Suwaki, Natsuko ^a,f   Bouwman, Peter ^b   Badie, Sophie ^a   Folio, Cecilia ^a   Benitez, Javier ^c   Gomez Lopez, Gonzalo ^c   Pisano, David G ^c   Jonkers, Jos ^b   Tarsounas, Madalena ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BRCA2 PROTEIN; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; DUAL SPECIFICITY PHOSPHATASE 7; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; RAD51 PROTEIN; UNCLASSIFIED DRUG; BRCA2 PROTEIN, HUMAN; BRCA2 PROTEIN, MOUSE; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; RAD51 PROTEIN, HUMAN; RAD51 PROTEIN, MOUSE; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GENE DELETION; GENOME; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HAMSTER; HELA CELL LINE; METABOLISM;

ANIMALS; BRCA2 PROTEIN; CELL LINE; CRICETINAE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; EPIGENESIS, GENETIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MICE; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES; RAD51 RECOMBINASE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899098006     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3697     Document Type: Article

References (70)

1. Gil, J. & Peters, G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7, 667-677 (2006).
2. Burri, N. et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab. Invest. 81, 217-229 (2001).
3. Watanabe, T., Nakamura, M., Yonekawa, Y., Kleihues, P. & Ohgaki, H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol. 101, 185-189 (2001).
4. Ho, G. H. et al. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. Breast Cancer Res. Treat. 65, 225-232 (2001).
5. Ichimura, K. et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 60, 417-424 (2000).
6. Toledo, F. & Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 (2008).
7. Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997).
8. Brooks, C. L. & Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315 (2006).
9. Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA 95, 8292-8297 (1998).
10. Pomerantz, J. et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723 (1998).
11. Sharpless, N. E. & DePinho, R. A. Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113, 160-168 (2004).
12. Sherr, C. J. et al. p53-Dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harb. Symp. Quant. Biol. 70, 129-137 (2005).
13. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220-228 (2010).
14. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006).
15. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355 (2008).
16. Polo, S. E. & Jackson, S. P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 25, 409-433 (2011).
17. Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529-542 (2011).
18. Hashimoto, Y., Ray Chaudhuri, A., Lopes, M. & Costanzo, V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat. Struct. Mol. Biol. 17, 1305-1311 (2010).
19. Evers, B. & Jonkers, J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25, 5885-5897 (2006).
20. Venkitaraman, A. R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. 4, 461-487 (2009).
21. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
22. Silver, D. P. & Livingston, D. M. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol. Cell 8, 233-243 (2001).
23. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004).
24. Stott, F. J. et al. The alternative product from the human CDKN2A locus, p14 ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014 (1998).
25. Khan, S. H., Moritsugu, J. & Wahl, G. M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc. Natl Acad. Sci. USA 97, 3266-3271 (2000).
26. Jazayeri, A. et al. ATM- and cell cycle dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37-45 (2006).
27. Mimitou, E. P. & Symington, L. S. DNA end resection-Unraveling the tail. DNA Rep. (Amst.) 10, 344-348 (2011).
28. Bunting, S. F. et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol. Cell 46, 125-135 (2012).
29. Dupré, A. et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat. Chem. Biol. 4, 119-125 (2008).
30. West, S. C. Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell Biol. 4, 1-11 (2003).
31. Badie, S. et al. BRCA2 acts as RAD51 loader to facilitate telomere replication and capping. Nat. Struct. Mol. Biol. 17, 1461-1469 (2010).
32. Charrier, J. D. et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 54, 2320-2330 (2011).
33. Schoppy, D. W. et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 122, 241-252 (2011).
34. Gilad, O. et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 70, 9693-9702 (2010).
35. Lin, W. C., Lin, F. T. & Nevins, J. R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 15, 1833-1844 (2001).
36. Chen, D., Shan, J., Zhu, W. G., Qin, J. & Gu, W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 464, 624-627 (2010).
37. Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413-431 (2009).
38. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
39. Keyse, S. M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27, 253-261 (2008).
40. Jeffrey, K. L., Camps, M., Rommel, C. & Mackay, C. R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 6, 391-403 (2007).
41. Spain, B. H., Larson, C. J., Shihabuddin, L. S., Gage, F. H. & Verma, I. M. Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. Proc. Natl Acad. Sci. USA 96, 13920-13925 (1999).
42. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
43. Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005).
44. Kamijo, T. et al. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled Atm Function1. Cancer Res. 59, 2464-2469 (1999).
45. Parrinello, S. et al. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 5, 741-747 (2003).
46. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009).
47. Velimezi, G. et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol. 15, 1260 (2013).
48. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006).
49. Crook, T., Crossland, S., Crompton, M. R., Osin, P. & Gusterson, B. A. p53 mutations in BRCA1-associated familial breast cancer. Lancet 350, 638-639 (1997).
50. Cheung, A. M. et al. Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice. Cancer Res. 64, 1959-1965 (2004).
51. Sherr, C. J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673 (2006).
52. Balko, J. M. et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18, 1052-1059 (2012).
53. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
54. Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537-549 (2009).
55. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
56. Blasco, M. A. et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34 (1997).
57. Palmero, I. & Serrano, M. Induction of senescence by oncogenic Ras. Methods Enzymol. 333, 247-256 (2001).
58. Tarsounas, M. et al. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 117, 337-347 (2004).
59. Sage, J., Miller, A. L., Pérez-Mancera, P. A., Wysocki, J. M. & Jacks, T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424, 223-228 (2003).
60. Denchi, E. L. & de Lange, T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448, 1068-1071 (2007).
61. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
62. Deng, Y., Guo, X., Ferguson, D. O. & Chang, S. Multiple roles for MRE11 at uncapped telomeres. Nature 460, 914-918 (2009).
63. Bugaut, A. & Balasubramanian, S. 5′ -UTR RNA G-quadruplexes: translation regulation and targeting. Nucleic Acids Res. 40, 4727-4741 (2012).
64. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
65. Jackson, D. A. & Pombo, A. Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J. Cell Biol. 40, 1285-1295 (1998).
66. Lin, S. M., Du, P., Huber, W. & Kibbe, W. A. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res. 36 (2008).
67. Smyth, G. K., Michaud, J. & Scott, H. S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067-2075 (2005).
68. Tarsounas, M., Davies, D. & West, S. C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 22, 1115-1123 (2003).
69. Min, J. et al. The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis. J. Biol. Chem. 287, 5091-5101 (2012).
70. Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 22315-22319 (2006).